Publicacións (25) Publicacións nas que participase algún/ha investigador/a

filter_list Endocrinology

2024

  1. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  2. The Role of Natriuretic Peptides in Pericardial Fluid in Predicting Cardiovascular Disorders: A Systematic Review

    Cardiology in Review

2023

  1. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  2. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease

    Nefrologia, Vol. 43, Núm. 4, pp. 386-398

  3. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Impact of Enhanced Phagocytosis of Glycated Erythrocytes on Human Endothelial Cell Functions

    Cells, Vol. 11, Núm. 14

  2. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2020

  1. Enhanced oxidative stress and damage in glycated erythrocytes

    PLoS ONE, Vol. 15, Núm. 7 July

2019

  1. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

2017

  1. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia

    Journal of Clinical Lipidology, Vol. 11, Núm. 1, pp. 260-271

2016

  1. Documento de consenso y recomendaciones sobre el uso de los péptidos natriuréticos en la práctica clínica

    Revista Clinica Espanola, Vol. 216, Núm. 6, pp. 313-322

2013

  1. Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion, and mobilization of GLUT-4

    Endocrinology, Vol. 154, Núm. 12, pp. 4757-4767

2012

  1. Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES

    Medicina Clinica, Vol. 138, Núm. 12, pp. 505-511

2011

  1. Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease

    European Journal of Endocrinology, Vol. 164, Núm. 4, pp. 529-537

2010

  1. Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels

    International Journal of Obesity, Vol. 34, Núm. 7, pp. 1200-1208

  2. Testosterone and cholesterol vasodilation of rat aorta involves L-type calcium channel inhibition

    Advances in Pharmacological Sciences, Vol. 2010

2009

  1. Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study

    Medicina Clinica, Vol. 132, Núm. 8, pp. 291-297

  2. La cistatina C aporta más información que otros parámetros de función renal en la estratificación del riesgo de los pacientes con síndrome coronario agudo

    Revista Espanola de Cardiologia, Vol. 62, Núm. 5, pp. 510-519

2008

  1. Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-diabetes

    Revista Espanola de Cardiologia, Vol. 61, Núm. 11, pp. 1168-1177

2007

  1. Prevalencia del síndrome metabôlico en pacientes con enfermedad cardiovascular en España: Estudio CLYDIA

    Medicina Clinica, Vol. 128, Núm. 11, pp. 407-413